Devicemakers slow to embrace green technology; Stryker says device tax will cost it $130M a year;

 @FierceMedDev: Budget battles could unravel the massive device/drug user fee renewal agreed to earlier this summer. More | Follow @FierceMedDev

 @MarkHFierce: Another day, another 510(k) for an Impella heart pump variation. The company is working hard to broaden its market. Release | Follow @MarkHFierce

 @DamianFierce: San Antonio's BiO2 Medical pulled in $12M to market its venous catheter. News | Follow @DamianFierce

> The medical device industry has been slow to embrace sustainability or pursue the recycling of used devices, Waste & Recycling News reports. Story

> Stryker's ($SYK) interim CEO Curt Hartman says that the medical device tax will cost his company about $130 million annually, according to MassDevice. Story

> Tissue Regeneration Systems, a developer of tissue-regeneration medical devices and related equipment, has secured $1 million in new financing. Item

> China has a robust demand for certain, hospital-focused medical devices made in the U.S., Buffalo Business First explains. Story

> Endologix ($ELGX) snagged a CE mark for Nellix, a device designed to seal abdominal aortic aneurysms. Article

> As medical device companies expand into emerging markets, more and more are using overseas CROs to conduct clinical trials, according to a new study. More

> Indian devicemaker Opto Circuits snagged regulatory approval in that country for its E-Magic Plus drug-eluting stent. News

Biotech News

 @FierceBiotech: What's killing biopharma's R&D success rate? Story | Follow @FierceBiotech

 @JohnCFierce: AZ does a China development deal on RA drug with WuXi AppTech. Kinda similar to SFJ pacts. Look for more of these. Report | Follow @JohnCFierce

> What's killing biopharma's R&D success rate? More

> Geron in meltdown as lead cancer drug crumbles in Phase II. Report

> Atlas R&D group banks $8M in virtual development deal. Story

> Peregrine soars on promising survival data for lung cancer drug. Article

Pharma News

 @FiercePharma: Truvada use expected to be limited in U.S. Story | Follow @FiercePharma

> FDA gives generic drugs 'super' status. Report

> Biogen Idec cashes out royalties on Benlysta. Article

> Budget impasse imperils FDA user fees programs. More

Biotech IT News

> Pharma flocks to social media analytics. Story

> Pinterest attracts more pharma outfits. Report

> ENCODE generates 15 trillion bytes of data for researchers. Article

> Informatics research may kill old-school databases. More

CRO News

> Top Emerging CRO Markets. Special Report

> Icon teams with Dublin university for drug development. Item

> FDA slaps DPT with warning letter over sterility concerns. Article

> CMO Patheon sells off clinical packaging biz. More

Suggested Articles

The AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.